Marieke van Son

78 CHAPTER 4 33. Wojcieszek, P.; Szlag, M.; Glowacki, G.; Cholewka, A.; Gawkowska-Suwinska, M.; Kellas-Sleczka, S.; Bialas, B.; Fijalkowski, M. Salvage high-dose-rate brachythera- py for locally recurrent prostate cancer after primary radiotherapy failure. Ra- diother Oncol 2016, 119, 405-410; DOI: 10.1016/j.radonc.2016.04.032. 34. Nguyen, P.L.; Alibhai, S.M.; Basaria, S.; D’Amico, A.V.; Kantoff, P.W.; Keating, N.L.; Penson, D.F.; Rosario, D.J.; Tombal, B.; Smith, M.R. Adverse effects of andro- gen deprivation therapy and strategies to mitigate them. Eur Urol 2015, 67, 825- 836; DOI: 10.1016/j.eururo.2014.07.010. 35. Peters, M.; Moman, M.R.; van der Poel, H.G.; Vergunst, H.; de Jong, I.J.; Vijverberg, P.L.; Battermann, J.J.; Horenblas, S.; van Vulpen, M. Patterns of outcome and tox- icity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: A multi-center ex- perience and literature review. World journal of urology 2013, 31, 403-409; DOI: 10.1007/s00345-012-0928-8. 36. Tran, H.; Kwok, J.; Pickles, T.; Tyldes- ley, S.; Black, P.C. Underutilization of local salvage therapy after radiation therapy for prostate cancer. Urol Oncol 2014, 32, 701-706; DOI: 10.1016/j.uro- lonc.2013.12.014. 37. Agarwal, P.K.; Sadetsky, N.; Konety, B.R.; Resnick, M.I.; Carroll, P.R.; Cancer of the Prostate Strategic Urological Research, E. Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and out- comes. Cancer 2008, 112, 307-314; DOI: 10.1002/cncr.23161. 38. Abuzallouf, S.; Dayes, I.; Lukka, H. Base- line staging of newly diagnosed prostate cancer: A summary of the literature. The Journal of urology 2004, 171, 2122-2127. 39. Hovels, A.M.; Heesakkers, R.A.; Adang, E.M.; Jager, G.J.; Strum, S.; Hoogeveen, Y.L.; Severens, J.L.; Barentsz, J.O. The diagnostic accuracy of ct and mri in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis. Clinical radiology 2008, 63, 387-395; DOI: 10.1016/j.crad.2007.05.022. 40. Evangelista, L.; Guttilla, A.; Zattoni, F.; Muzzio, P.C.; Zattoni, F. Utility of choline positron emission tomography/comput- ed tomography for lymph node involve- ment identification in intermediate- to high-risk prostate cancer: A systematic literature review and meta-analysis. Eur Urol 2013, 63, 1040-1048; DOI: 10.1016/j. eururo.2012.09.039. 41. Evangelista, L.; Zattoni, F.; Guttilla, A.; Saladini, G.; Zattoni, F.; Colletti, P.M.; Rubello, D. Choline pet or pet/ct and biochemical relapse of prostate cancer: A systematic review and meta-anal- ysis. Clinical nuclear medicine 2013, 38, 305-314; DOI: 10.1097/RLU.0b013e- 3182867f3c. 42. Wallitt, K.L.; Khan, S.R.; Dubash, S.; Tam, H.H.; Khan, S.; Barwick, T.D. Clinical pet imaging in prostate cancer. Radio- graphics : a review publication of the Radiological Society of North America, Inc 2017, 37, 1512-1536; DOI: 10.1148/ rg.2017170035. 43. Perera, M.; Papa, N.; Christidis, D.; Wetherell, D.; Hofman, M.S.; Murphy, D.G.; Bolton, D.; Lawrentschuk, N. Sensi- tivity, specificity, and predictors of posi- tive (68)ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A sys- tematic review and meta-analysis. Eur Urol 2016, 70, 926-937; DOI: 10.1016/j. eururo.2016.06.021.